Lung Cancer Iressa Rises From the Ashes

Introduction

Due to the high patient potential and unmet needs of lung cancer, there has been significant R&D interest from pharmaceutical and biotechnology companies, and the first of the innovative agents for the disease are beginning to enter the market. Yet, cytotoxics will remain the key to lung cancer treatment and innovative agents will be used in conjunction with existing agents.

Scope

The importance of clinical trial designs in lung cancer 

Epidemiology of non-small cell (NSCLC) and small cell lung cancer (SCLC) in the seven major markets 

Profiles and potential of key late-stage drugs in development for lung cancer, including global sales forecast to 2011 

Opinion leader views on lung cancer pipeline drugs profiled by Datamonitor 

Report Highlights

AstraZeneca’s Iressa is approved in Japan and the US despite the controversies surrounding the drug and Datamonitor believes that Iressa will become one of the main drivers of the market. Lilly’s Alimta is also expected to make significant impact in the market and become the gold standard for malignant mesothelioma.

Reasons to Purchase

Identify key drugs in late-stage development for lung cancer to determine their competition and entry strategies into the lung cancer market 

Assess the sales forecast of new drug classes for lung cancer to assess the commercial potential of pipeline drugs

Choose the right clinical trial endpoints for lung cancer pipeline drugs to maximize the chance of gaining approval 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a252